Increased expression of Protein S in eyes with diabetic retinopathy and diabetic macular edema

Masahiko Sugimoto1, Mineo Kondo1, Taro Yasuma2, Corina N. D’Alessandro-Gabazza2, Masaaki Toda2, Hisanori Imai3, Makoto Nakamura3 & Esteban C. Gabazza2

Protein S (PS) is a multifunctional glycoprotein that ameliorates the detrimental effects of diabetes mellitus (DM). The aim of this study was to evaluate the distribution of PS in diabetic retinopathy (DR) and diabetic macular edema (DME). This was a study of 50 eyes with DM (37 with DME, 6 with proliferative DR, and 7 with no DR) and 19 eyes without DM. The level of PS was measured by enzyme immunoassay and was compared between eyes with or without DM, with or without DME, and with severe DME (≥ 350 μm) or mild DME (< 350 μm). We also performed immunohistopathologic evaluations of post-mortem eyes and the cystoid lesions excised during surgery. The aqueous free PS was significantly higher with DM (7.9 ± 1.2 ng/ml, \( P < 0.01 \)) than without DM (6.1 ± 0.7). The aqueous free PS was significantly elevated with DME (8.2 ± 1.2, \( P < 0.05 \)) compared to proliferative DR (7.0 ± 1.0) and no DR (7.0 ± 0.7). Eyes with severe DME had significantly higher aqueous free PS than mild DME (8.5 ± 1.3 vs. 7.7 ± 1.0, \( P < 0.05 \)). Immunohistochemistry showed PS in the outer plexiform layer of the retina and cystoid lesion. The higher expression of PS with DR and DME suggests that PS is involved in their pathogenesis.

There are approximately 400 million people with diabetes mellitus (DM) worldwide, and it has been estimated that the number will reach 600 million in 20 years1. DM is characterized by the destruction of the pancreatic β cells leading to impaired insulin secretion, hyperglycemia, and chronic microangiopathy2. Common microvascular complications of DM include peripheral neuropathy, nephropathy, and retinopathy. Diabetic retinopathy (DR) causes severe visual disturbances due to retinal ischemia in eyes and an increase of retinal permeability leading to diabetic macular edema (DME)3. The retinal ischemia causes protein leakage and edema because of the disruption of the blood-retinal barrier between the retinal vascular endothelium and retinal pigment epithelium4. The prevalence of DME is different from that of DR and not all DM patients develop DME. An earlier study showed that among 22,896 DM patients, the overall prevalence of DR was 34.6% and that for DME was 6.81%5.

The angiogenic and inflammatory responses in eyes with DR play a critical role in the progression of DR and DME. The presence of inflammation has led to a growing interest in developing inhibitors of the inflammation to treat these retinal disorders. In this context, the pro-inflammatory and angiogenic vascular endothelial growth factor (VEGF) is an important therapeutic target, and anti-VEGF agents are currently the first-line treatment for DME. Inhibitors of inflammation, including steroids, e.g., triamcinolone acetonide, dexamethasone, and fluocinolone acetonide, are also used to treat non-responders of anti-VEGF agents. However, no curative therapy is currently available for DME. Therefore, identifying the mechanism-associated factors and developing biomarkers for the early detection of these disorers are of critical importance.

Protein S (PS) is a 75-kDa vitamin K-dependent glycoprotein that regulates inflammation by inhibiting the coagulation system, the expression of inflammatory cytokines from several types of cells, and apoptosis6. PS regulates inflammation and apoptosis by binding to the Tyro3, Axl, and Mer (TAM) tyrosine kinase receptors7–8. PS circulates in the plasma in a free form and can complex with C4b-binding protein (C4BP), an inhibitor of the classic complement pathway. Both the free form of PS (free PS) and complex form of PS exert anti-inflammatory activity. For example, PS in complex with C4BP inhibits complement-mediated inflammation by localizing C4BP to the cell membrane9. These reported beneficial effects suggest the potential therapeutic application of PS for inflammatory diseases10.
There was also no significant difference in the aqueous humor concentrations of total PS (36.1 ± 11.2 ng/ml vs 4.2 ± 0.4 μg/ml vs 5.0 ± 0.9 μg/ml vs 4.5 ± 1.3 μg/ml) among the DME, NDR and PDR groups (Fig. 2a–c). Among the three groups (Fig. 2d,f). The concentration of free PS in the aqueous humor was 8.2 ± 1.2 ng/ml in the DME group which was significantly higher than the 7.0 ± 0.7 ng/ml in the NDR group and the 7.0 ± 1.0 ng/ml in the PDR group (P = 6.78 × 10⁻⁷; Fig. 2e).

The concentration of free PS in the aqueous humor of patients with DM was 38.6 ± 16.3 ng/ml which was not significantly different from that in patients without DM at 35.6 ± 12.2 ng/ml (P > 0.05; Fig. 1a,d). The plasma concentrations of free PS in patient with DM with DME was 3.0 ± 0.4 μg/ml which was significantly lower than that in patients without DM at 3.6 ± 0.9 μg/ml (P = 0.01). The plasma concentration of C4BP was 4.3 ± 0.7 μg/ml in patients with DM which was significantly lower than the 5.4 ± 1.4 μg/ml in patients without DM (P = 0.01 Fig. 1b,c). The concentration of free PS in the aqueous humor was 7.9 ± 1.2 ng/ml in patients with DM which was significantly higher than that in non-DM patients at 6.1 ± 0.7 ng/ml (P = 6.20 × 10⁻⁹; Fig. 1e). There was no significant difference in the concentration of C4BP in the aqueous humor between the DM group (17.1 ± 8.2 ng/ml) and non-DM group (15.8 ± 11.4 ng/ml; Fig. 1f).

### Plasma and aqueous humor levels of PS and related molecules in patients with and without DM.

The concentration of total PS in the plasma of patients with DM was 18.5 ± 5.9 μg/ml which was not significantly different from that in patients without DM at 20.2 ± 4.5 μg/ml (P > 0.05). The concentration of PS in the aqueous humor of patients with DM was 38.6 ± 16.3 ng/ml which was not significantly different from that in patients without DM at 35.6 ± 12.2 ng/ml (P > 0.05; Fig. 1a,d). The plasma concentrations of free PS in patient with DM was 3.0 ± 0.4 μg/ml which was significantly lower than that in patients without DM at 3.6 ± 0.9 μg/ml (P = 0.01). The plasma concentration of C4BP was 4.3 ± 0.7 μg/ml in patients with DM which was significantly lower than the 5.4 ± 1.4 μg/ml in patients without DM (P = 0.01 Fig. 1b,c). The concentration of free PS in the aqueous humor was 7.9 ± 1.2 ng/ml in patients with DM which was significantly higher than that in non-DM patients at 6.1 ± 0.7 ng/ml (P = 6.20 × 10⁻⁹; Fig. 1e). There was no significant difference in the concentration of C4BP in the aqueous humor between the DM group (17.1 ± 8.2 ng/ml) and non-DM group (15.8 ± 11.4 ng/ml; Fig. 1f).

### Plasma and aqueous humor levels of PS and related molecules in DME, non-DR, and PDR groups.

There was no significant difference in the plasma concentrations of total PS (18.6 ± 6.5 μg/ml vs 17.1 ± 5.2 μg/ml vs 19.9 ± 4.1 μg/ml), free PS (3.1 ± 0.4 μg/ml vs 2.8 ± 0.2 μg/ml vs 2.8 ± 0.4 μg/ml), and C4BP (4.2 ± 0.4 μg/ml vs 5.0 ± 0.9 μg/ml vs 4.5 ± 1.3 μg/ml) among the DME, NDR and PDR groups (Fig. 2a–c). There was also no significant difference in the aqueous humor concentrations of total PS (36.1 ± 11.2 ng/ml vs 48.3 ± 33.8 ng/ml vs 42.8 ± 10.0 ng/ml), and C4BP (14.8 ± 4.4 ng/ml vs 22.5 ± 14.7 ng/ml vs 24.1 ± 10.3 ng/ml) among the three groups (Fig. 2d,f). The concentration of free PS in the aqueous humor was 8.2 ± 1.2 ng/ml in the DME group which was significantly higher than the 7.0 ± 0.7 ng/ml in the NDR group and the 7.0 ± 1.0 ng/ml in the PDR group (P = 6.78 × 10⁻⁷; Fig. 2e).

### Severity of DME and ocular PS concentration.

Because there was a high concentration of free PS in the aqueous humor in the DME group, we divided the eyes with DME into two groups: a group with severe DME (CRT ≥ 350 μm, n = 25) and a group with mild DME (CRT < 350 μm, n = 12). The demographics of the patients are shown in Table 2. The values of the different parameters were not significantly different between the two groups other than CMT. The aqueous humor level of free PS was significantly higher in the group with severe DME than the group with mild DME (8.5 ± 1.3 ng/ml vs 7.7 ± 1.0 ng/ml, P = 0.04, Fig. 3a). The aqueous humor

| N | Age (years) | HbA1c (%) | FBS (mg/dL) | BUN (mg/dL) | eGFR (mL/min/1.73m²) | DBP (mmHg) | SBP (mmHg) |
|---|---|---|---|---|---|---|---|
| DM (+) | 37 | 65.3 ± 12.6 | 7.8 ± 1.6 | 173.3 ± 65.9 | 20.0 ± 12.9 | 65.9 ± 32.2 | 141.6 ± 20.5 | 73.0 ± 10.8 |
| DME | 7 | 75.0 ± 5.9* | 6.5 ± 0.3 | 135.1 ± 36.9 | 19.9 ± 6.9 | 72.2 ± 16.3 | 139.9 ± 17.6 | 71.3 ± 13.1 |
| NDR | 6 | 67.5 ± 10.4 | 7.9 ± 1.9 | 182.3 ± 34.3 | 21.2 ± 9.1 | 52.5 ± 27.5 | 140.3 ± 29.9 | 73.0 ± 12.3 |
| PDR | 50 | 68.2 ± 10.0 | 7.6 ± 1.6 | 168.5 ± 58.9 | 20.1 ± 11.6 | 65.1 ± 29.7 | 141.1 ± 21.0 | 72.8 ± 11.1 |
| Total | 19 | 73.5 ± 7.5 | - | 107.1 ± 15.4* | 14.9 ± 3.2 | 70.3 ± 12.5 | 138.4 ± 15.6 | 78.1 ± 8.3 |

*P value 0.0003* 0.07 0.0001* 0.79 0.86 0.94 0.56

Table 1. Demographics of all patients. BUN: blood urea nitrogen, DBP: diastolic blood pressure, DM: diabetes mellitus, DME: diabetic macular edema, eGFR: estimated glomerular filtration rate, FBS: fasting blood sugar, HbA1c: hemoglobin A1c, NDR: no diabetic retinopathy, PDR: proliferative diabetic retinopathy, SBP: systolic blood pressure. *: P < 0.05, Kruskal–Wallis test.
concentrations of total PS (37.6 ± 12.6 ng/ml vs 32.7 ± 6.6 ng/ml) and C4BP (14.6 ± 4.6 ng/ml vs 15.4 ± 4.0 ng/ml) were not significantly different between patients with severe and mild DME (Fig. 3b,c). The plasma concentrations of free PS (3.2 ± 0.4 μg/ml vs 3.0 ± 0.3 μg/ml), total PS (19.5 ± 7.1 μg/ml vs 16.5 ± 4.8 μg/ml), and C4BP (4.2 ± 0.5 μg/ml vs 4.1 ± 0.3 μg/ml) were not significantly different (Fig. 3d–f) between the two groups.

Localization of PS in human retina. We stained the retina of post-mortem human eyes to determine the expression sites of PS in eyes with DM. The retina of the eyes from a non-DM patient (62-years-old, woman; Fig. 4a,d) did not have any localized staining for PS. However, PS staining was positive in the outer plexiform layer (OPL) of the diabetic eyes of a 93-year-old man with NPDR (Fig. 4b,e) and a 60 years-old man with PDR (Fig. 4c,f).

PS location in cystoid lesion in eyes with DME. We collected specimens of the cystoid lesions for PS staining in eyes with DME during pars plana vitrectomy. The specimens stained positive for PS (Fig. 5a,b).

Discussion

Macular edema is the accumulation of extravascular fluid in the OPL, the inner nuclear layer, and the Müller cells leading to localized expansion15. Cystoid macular edema has a perifoveal configuration with cyst-like spaces due to fluid accumulation16,17. The presence of cystic changes in eyes with DME in the OPL is common by pathological examinations18. Byeon et al. also reported cysts within the outer plexiform and OPL that may be related to leaky vessels when examined by OCT19. The cysts frequently progress and become hard exudates in the outer plexiform and outer nuclear layers. Deposits of the hard exudates causes irreversible retinal damages leading to loss of central visual function. Thus, the evidence suggests that the outer plexiform and outer nuclear layers are major sites of tissue injury in DME. Our findings showed an increase of free PS in DM eyes particularly in severe DME, localized expression of PS in the OPL, and within cysts in cystic DME. These findings suggest the close association of PS expression with the DME pathological conditions.

PS inhibits the coagulation system by increasing the activity of activated protein C (APC), an anticoagulant protein20. PS can accelerate fibrinolysis by suppressing the activation of thrombin-activatable fibrinolysis inhibitor or by supporting the APC-mediated inhibition of plasminogen activator inhibitor-121. Fibrinogen is a soluble
macro-molecule that forms an insoluble clot or gel after conversion to fibrin\(^2\). The C4BP-PS complex may accelerate fibrin degradation during inflammation by interacting with plasminogen\(^23\). This increased interaction of C4BP and PS with plasminogen accelerates the plasminogen activator-mediated conversion of plasminogen to plasmin on the fibrin surface which leads to increased fibrinolysis. Mass spectrometry analysis has shown that the components of the cystoid lesion in eyes with DME is composed of microfibrin wrapped in collagen fibrils and fibrinogen\(^24\). Based on these observations, we suggest that the PS present in the OPL and inside the cystoid lesion activates the fibrinolysis pathway to reduce the deposition of fibrin. This effect may also prevent hard exudates deposition that causes irreversible retinal damage. The results of earlier studies have shown that PS protects the blood–brain barrier from hypoxic/ischemic damage through its Tyro3 receptor, and mice deficient in PS develop embryonic lethal coagulopathy with disruption of the blood–brain barrier\(^25,26\). Based on these observations, we can speculate that PS protects against blood-retinal barrier disruption which contributes significantly to protein leakage with DME and it may explain our observation, significant higher the aqueous humor levels of free PS level in the DME group compared to the NPDR and PDR groups. But because small number of samples were evaluate PS levels in PDR and NPDR for ELISA which was not balanced, this may affect the results. In addition,
we could obtain a few number of post-mortem eye with DM because of the difficulty to obtain post-mortem eye for research in Japan. We need further investigation with many number of tissue samples.

An interesting observation was the discrepant levels of free PS in plasma and aqueous humor. While there was decreased levels of free PS in plasma, the free PS level was increased in the aqueous humor. Synthesis and release of PS by cells in the eyes may explain these findings. However, although vascular endothelial cells can secrete PS, there is no evidence showing the expression of PS by retinal capillary endothelial cells. The biological significance of the elevated level of PS in the eyes with DM is also unclear. Although the local increase of PS in the eyes may be a compensatory response to an enhanced retinal injury, a detrimental role of PS in disease pathogenesis also deserves consideration. Such dissociation of the molecule between local and systemic distribution is sometimes observed for other molecules. Though many cytokines are expressed in skeletal muscle following exercise, some of them are not released into the circulation at least in large amounts because they are produced locally and sufficient quantities of cytokines to increase their concentration in the systemic circulation may not be secreted. But because our histological examination could not certify the origin of the PS expression, it is not clear whether similar spiculation can explain dissociation of local and systemic PS distribution. We need much consideration for this matter in the further study.

On the contrary, there were several reports about unfavorable effects of PS. PS exacerbates acute liver injury by prolonging the natural killer T cells survival and worsens liver fibrosis by inhibiting apoptosis of extracellular matrix-producing fibroblasts. The expression of PS may also be disease stage-related. Zhong et al. have reported a high glomerular level of PS in early stages and low glomerular PS level in late stages of diabetic nephropathy despite the normal circulating level of PS. There is a possibility that PS distribution may differ among the stage of disease. However, the occurrence of DME is not related to the clinical stage of DR. Based on our present findings, we suggest that PS expression is not related to the stage of DR and that PS expression only increases in DME. Therefore, detecting PS expression may be a biomarker for the early diagnosis of DME before the abnormalities are detected by OCT or ophthalmoscopy. However, further investigations are needed to corroborate these findings.

Though we reported importance of PS in diabetic retina, there are some limitations in this study including the small number of samples. First, the inclusion of a larger number of eyes with cyst-type DME than sponge- or serous-type DME are limitations of the present study. There is a possibility that PS behavior differ with other type of DME like sponge or serous type. The relationship between the retinal morphologic changes and concentrations of intravitreal cytokines in eyes with DME was reported and the significant association of serus type DME with
Figure 4. Location of protein S in the human retina with and without diabetes. The retina of post-mortem human eyes was stained with a PS antibody. No staining was observed in the retina from patients without DM (62-years-old, woman, (a)). PS is present in the OPL of patients with DM (b, 93-year-old, man with NPDR; 60-year-old, man with PDR). Black arrow heads shows localization of PS on OPL. Magnified images of each images were shown (d–f). DM, diabetes mellitus; NPDR, non-proliferative diabetic retinopathy; OPL, outer plexiform layer; PDR, proliferative diabetic retinopathy; PS, protein S. Bar: 10 μm.

Figure 5. Location of Protein S in the components of a cystoid lesion with diabetic macular edema. The component of cystoid lesion with DME was stained with anti-hPS antibody. No staining was observed in the control nonspecific IgG (a). PS was identified inside the component of cystoid lesion (b). DME, diabetic macular edema; PS, protein S. Bar: 100 μm.
intravitreal interleukin-6 level was observed and which indicated that inflammation may play an important role in the development of serous type DME. Because there is a possibility PS may only affect the formation of cystic DME, we also need advanced examination for various DME type.

Second, the circadian rhythm is important for in the progression of arteriosclerosis and thrombosis. Undar et al. reported that plasma PS levels were also affected by circadian rhythm, significantly the highest at 6 a.m. and the lowest at noon. We did not take into account physiological chage of PS due to circadian variation. But they reported that no significant differences were observed at other hours and intervals. Though we collected samples at daily time (from 9 a.m to 5 p.m) when PS levels were not reported to be affected, we should take into account the effects of circadian rhythm.

And finally, Here we did not evaluate vitreous level of PS for DR and DME. There is a possibility that PS levels in vitreous fluid reflects PS levels in retina more sensitive. But some reports concern that there is a significant relationship between VEGF and interleukin-6 levels in aqueous humor and in vitreous fluid. Though it is not clear whether this is also applied for PS, we need consideration for this in the further study.

Our results showed the presence and increased expression of PS in eyes with DR and DME. The expression of PS was especially high in the OPL and cystoid lesions. These observations suggest that PS is involved in the pathogenesis of diabetic retinal complications, and it can be used as a biomarker and therapy for DME.

**Methods**

**Subjects.** The Mie University Ethics Committee for Clinical Investigations approved the investigation protocol (Approval #3087) and Kobe University Ethics Committee for Clinical Investigations approved the investigation protocol (Approval #B200233). The study was registered at [http://www.umin.ac.jp](http://www.umin.ac.jp) (UMIN ID 000033728). The procedures conformed to the tenets of the Declaration of Helsinki, and all patients signed an informed consent form before entry. The patients enrolled were patients in the Department of Ophthalmology and Endocrinology, Mie University Hospital and Kobe University. The clinical history of all patients was obtained from their medical records.

**Sample collection.** Blood serum samples were collected during regular checkups before receiving any ophthalmic treatments. The samples were centrifuged 400 x g for 5 min, the supernatants removed, and immediately stored at −80 °C until use. In addition, 50 µl of aqueous humor was collected before the ocular treatments. The samples were frozen immediately and stored at −80 °C until use. We did not collect any vitreous fluid because sampling can cause complications such as retinal detachments.

**Inclusion and exclusion criteria.** Patients that were ≥20-years with type 1 or type 2 DM and those with DR or DME were included in the DM group. The diagnosis of DME was based on findings of the fundus examinations and spectral-domain optical coherence tomography (OCT). The stage of diabetic nephropathy before treatment was obtained from the medical charts. Trained retinal specialists (M.S. and M.K.) examined the fundus by indirect ophthalmoscopy and wide field fundus imaging obtained by the Optos ultra-widefield imaging system (Optos Panoramic 200MA™, Optos PLC. Dunfermline, Scotland, UK). The severity of DR was classified into three groups from these evaluations: no DR (NDR), non-proliferative DR (NPDR), and proliferative DR (PDR) according to the International Clinical Diabetic Retinopathy Disease Severity Scale (DRSS). DME was defined as a central subfoveal macular thickness (CMT) of ≥250 µm measured as the mean retinal thickness in the central 1 mm diameter circle in the OCT images. Subjects with NDR or NPDR had no DME.

The exclusion criteria for patients with DM were: history of any pars plana vitrectomy, history of intravitreal or sub-tenon injections of any drugs including anti-VEGF agents within two months before the beginning of this study, eyes with any inflammatory disease, drusen, vitreous hemorrhage or retinal hemorrhage which involved the intra- or subfoveal spaces, glaucoma or intraocular pressure ≥21 mmHg, and media opacities that significantly affected the OCT images. Women with pregnancy, under fertility treatments or use of contraceptives were also excluded from all the groups.

We also collected aqueous humor from patients without DM during surgical procedures for cataract, macular hole, and retinal detachment. The inclusion criteria for patients without DM were: patients ≥20-years with no DM and IOP of ≤21 mmHg. The exclusion criteria for patients without DM were: patients with severe systemic disorders, any history of other ocular diseases, history of pars plana vitrectomy, or glaucoma. DME eyes were also divided into two groups based on CMT measurement: a group with severe DME (higher CMT more than 350 µm) and a group with mild DME (lower CMT less than 350 µm).

The exclusion criteria for both DM patients and non-DM control subjects were: uncontrolled systemic medical conditions, history of a thromboembolic event or ischemic disease including myocardial infarction or cerebral infarction, prior treatment with anticoagulants, i.e., aspirin or with systemic anti-VEGF agents, i.e., bevacizumab, diagnosis of diseases causing hypercoagulability, high refractive errors (spherical equivalent > –3 or +3 diopters, axial lengths longer than 24.0 mm or less than 22.0 mm, and amблиopia.

Hematological analyses were done before the treatment to measure the level of fasting blood sugar (FBS, normal value 70–110 mg/dL), hemoglobin A1c (HbA1c, NGSP, normal value 4.9–6.0%), blood urea nitrogen (BUN, normal value 8–20 mg/dL), and estimated glomerular filtration rate (eGFR, normal value 60–120 ml/ min/1.73 m²). The blood pressure was also measured before beginning the treatment.

**Immunooassays.** To determine the level of free human PS (hPS), a 96-well microplate was coated with C4BP (ATGen Corp., Sampyeong-dong, Korea), and after appropriate washing and blocking, samples were incubated to allow free hPS to bind C4BP. Then, biotin-labeled polyclonal rabbit anti-hPS antibody (Dako Cytomation,
Glostrup, Denmark) was added. Complement C4BP was measured using an enzyme immunoassay kit from Assaypro (St. Charles, MO) and the total hPS as described.  

**Immunohistochemical examination of human eyes.** Post-mortem human eyes were obtained from the National Disease Research Interchange (Philadelphia, PA) fixed in formalin and embedded in paraffin. The postmortem time ranged from 14 to 24 h. The slides were deparaffinized in xylene and rehydrated through an alcohol series for staining. Endogenous peroxidase was blocked by immersion in 0.3% hydrogen peroxidase for 30 min. Slides were incubated with goat polyclonal anti-hPS antibody (A0384, DAKO, Glostrup, Denmark) followed by treatment with horseradish peroxidase. Samples were examined with a fluorescence microscope (BZ-9000: Keyence, Osaka, Japan).

**En bloc removal of the component of cystoid lesion.** The components of cystoid lesions in eyes with DME were collected during pars plana vitrectomy. The surgical procedure for en bloc extraction of cystoid lesion component combined with pars plana vitrectomy in DME patients was described in detail. Briefly, after incision of the external wall of the subfoveal cystoids with a 27-gauge instrument, the exposed components of the cystoid lesions were grasped by forceps and excised en bloc. After removal, the cystoid lesion components were stored at −80 °C and embedded in paraffin at the time of examination.

**Statistical analyses.** Data are presented as the means ± standard deviations. The significance of the differences between two variables was determined by Mann–Whitney U-tests and between three or more variables by the Kruskal–Wallis test with the Scheffe test. A P < 0.05 was considered significant.

Received: 8 February 2021; Accepted: 4 May 2021
Published online: 17 May 2021

**References**

1. Wild, S. et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care* **27**, 1047–1053 (2004).
2. American Diabetes Association. Classification and diagnosis of diabetes. *Diabetes Care* **38**(Suppl), S8–S16 (2015).
3. Klein, R., Klein, B. E. & Moss, S. E. Visual impairment in diabetes. *Exp. Eye Res.* **81**, 581–591 (2005).
4. Scholl, S., Kirchhof, J. & Augustin, A. I. Pathophysiology of macular edema. *Ophthalmologica* **224**(Suppl 1), 1–8 (2010).
5. Wolter, J. R. The histopathology of cystoid macular edema. *Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol.* **216**, 85–101 (1981).
6. Rotsos, T. G. & Moschos, M. S. Cystoid macular edema. *Clin. Ophthalmol.* **2**, 919–930 (2008).
7. Tso, M. O. Pathology of cystoid macular edema. *Ophthalmologica* **89**, 902–915 (1982).
8. Byeon, S. H. et al. New insights into the pathoanatomy of diabetic macular edema: angiographic patterns and optical coherence tomography. *Retina* **32**, 1087–1099 (2012).
9. Dahlback, B. Vitamin K-dependent Protein S: Beyond the Protein C Pathway. *Semin. Thromb. Hemost.* **44**, 176–184 (2018).
10. Mosnier, L. O., Meijers, J. C. & Bouma, B. N. The role of protein S in the activation of thrombin activatable fibrinolysis inhibitor (TAFI) and regulation of fibrinolysis. *Thromb. Haemost.* **86**, 1040–1046 (2001).
11. Weiss, J. W. & Litvinov, R. I. Fibrin formation, structure and properties. *Subcell Biochem.* **82**, 405–456 (2017).
12. Agarwal, V., Talens, S., Grandits, A. M. & Blom, A. M. A novel interaction between complement inhibitor C4b-binding protein and plasminogen that enhances plasminogen activation. *J. Biol. Chem.* **290**, 13833–13842 (2015).
13. Imai, H. et al. Effectiveness of en bloc removal of fibrinogen-rich component of cystoid lesion for the treatment of cystoid macular edema. *Retina* **40**, 154–159 (2020).
14. Saller, F. et al. Generation and phenotypic analysis of protein S-deficient mice. *Blood* **114**, 2307–2314 (2009).
15. Zhu, D. et al. Protein S controls hypoxic/ischemic blood-brain barrier disruption through the TAM receptor Tyro3 and sphingosine 1-phosphate receptor. *Blood* **115**, 4963–4972 (2010).
16. Peake, J. M., Gatta, P. G., Suzuki, K. & Nieman, D. C. Cytokine expression and secretion by skeletal muscle cells: regulatory mechanisms and exercise effects. *Exerc Immunol. Rev.* **21**, 8–25 (2015).
17. Chellakkot-Govindalayathil, A. L. et al. Protein S exacerbates alcoholic hepatitis by stimulating liver natural killer T cells. *J. Thromb. Haemost.* **2015(13)**, 142–154 (2015).
18. Totoki, T. et al. Protein S exacerbates chronic liver injury and fibrosis. *Am. J. Pathol.* **188**, 1195–1203 (2018).
19. Zhong, F. et al. Protein S protects against podocyte injury in diabetic nephropathy. *J. Am. Soc. Nephrol.* **29**, 1397–1410 (2018).
20. Sonoda, S. et al. Retinal morphologic changes and concentrations of cytoxines in eyes with diabetic macular edema. *Retina* **34**, 741–748 (2014).
32. Man, A. W. C., Li, H. & Xia, N. Circadian rhythm: potential therapeutic target for atherosclerosis and thrombosis. Int. J. Mol. Sci. 22, 876 (2021).
33. Undar, L., Ertuğrul, C., Altunbaş, H. & Akça, S. Circadian variations in natural coagulation inhibitors protein C, protein S and antithrombin in healthy men: a possible association with interleukin-6. Thromb. Haemost. 81, 571–575 (1999).
34. Funatsu, H. et al. Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefes Arch. Clin. Exp. Ophthalmol. 243, 3–8 (2005).
35. Wilkinson, C. P. et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110, 1677–1682 (2003).

Acknowledgements
We thank Professor Emeritus Duco Hamasaki of the Bascom Palmer Eye Institute of the University of Miami for critical discussion and final manuscript revisions.

Author contributions
M.S., M.K., and E.C.G. conceived and coordinated the study, evaluated the patients, and wrote the paper. T.Y, C.N.D.G., and M.T. performed the experiments. M.S. take histological images. H.I. and M.N. performed surgery for the component of the cystoid lesion. All authors reviewed the results and approved the final version of the manuscript.

Funding
This research was supported in part by a Kakenhi Grant-in-Aid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (No. 18K09402) and Okasan-Kato Foundation 2017. The funders had no role in study design, data analysis, decision to publish, or preparation of the manuscript.

Competing interests
Masahiko Sugimoto have: [F] Alcon Pharma (class III), Bayer (class III). [J/E/C/P] None. [R] Alcon pharma (class II), Kowa Pharma (class II), Senjyu Pharma (class II), Daiichi Yakuhin Sangyo (class II), Bayer (class II), Wakamoto Pharma (class II).

Additional information
Correspondence and requests for materials should be addressed to M.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021